Total Payments
$435,517
2024 Payments
$322,026
Companies
19
Transactions
173
Payment Breakdown by Category
Consulting$355,599 (81.6%)
Travel$64,549 (14.8%)
Other$8,353 (1.9%)
Food & Beverage$5,556 (1.3%)
Research$1,460 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $355,599 | 44 | 81.6% |
| Travel and Lodging | $64,549 | 56 | 14.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $8,353 | 4 | 1.9% |
| Food and Beverage | $5,556 | 67 | 1.3% |
| Unspecified | $1,460 | 2 | 0.3% |
Payments by Type
General
$434,057
171 transactions
Research
$1,460
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Zealand Pharma A/S | $300,663 | 50 | $0 (2024) |
| Novo Nordisk Inc | $49,599 | 27 | $0 (2024) |
| Eli Lilly and Company | $23,327 | 31 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $22,436 | 7 | $0 (2018) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $18,065 | 20 | $0 (2024) |
| Eisai Inc. | $12,267 | 12 | $0 (2023) |
| Genentech, Inc. | $4,149 | 5 | $0 (2019) |
| PFIZER INC. | $1,433 | 2 | $0 (2020) |
| Amgen Inc. | $1,046 | 5 | $0 (2018) |
| Takeda Pharmaceuticals U.S.A., Inc. | $975.00 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $322,026 | 68 | Zealand Pharma A/S ($297,581) |
| 2023 | $43,324 | 49 | Eli Lilly and Company ($23,267) |
| 2022 | $12,418 | 8 | Novo Nordisk Inc ($11,672) |
| 2021 | $7,650 | 4 | Novo Nordisk Inc ($7,650) |
| 2020 | $1,400 | 1 | PFIZER INC. ($1,400) |
| 2019 | $4,149 | 5 | Genentech, Inc. ($4,149) |
| 2018 | $36,141 | 24 | SANOFI-AVENTIS U.S. LLC ($22,436) |
| 2017 | $8,409 | 14 | Eisai Inc. ($7,272) |
All Payment Transactions
173 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | Zealand Pharma A/S | — | Food and Beverage | In-kind items and services | $161.67 | General |
| 12/31/2024 | Zealand Pharma A/S | — | Food and Beverage | In-kind items and services | $152.67 | General |
| 12/31/2024 | Zealand Pharma A/S | — | Food and Beverage | In-kind items and services | $59.00 | General |
| 12/31/2024 | Zealand Pharma A/S | — | Food and Beverage | In-kind items and services | $55.00 | General |
| 12/31/2024 | Zealand Pharma A/S | — | Food and Beverage | In-kind items and services | $40.33 | General |
| 12/18/2024 | Zealand Pharma A/S | — | Consulting Fee | Cash or cash equivalent | $21,750.00 | General |
| 12/18/2024 | Zealand Pharma A/S | — | Travel and Lodging | In-kind items and services | $237.51 | General |
| 12/12/2024 | Zealand Pharma A/S | — | Consulting Fee | Cash or cash equivalent | $42,650.00 | General |
| 12/12/2024 | Zealand Pharma A/S | — | Travel and Lodging | In-kind items and services | $4,194.04 | General |
| 12/07/2024 | Zealand Pharma A/S | — | Consulting Fee | Cash or cash equivalent | $18,250.00 | General |
| 12/07/2024 | Zealand Pharma A/S | — | Consulting Fee | Cash or cash equivalent | $13,250.00 | General |
| 12/07/2024 | Zealand Pharma A/S | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,182.59 | General |
| 12/01/2024 | Zealand Pharma A/S | — | Food and Beverage | In-kind items and services | $48.02 | General |
| 12/01/2024 | Zealand Pharma A/S | — | Food and Beverage | In-kind items and services | $46.85 | General |
| 11/21/2024 | Zealand Pharma A/S | — | Food and Beverage | In-kind items and services | $28.84 | General |
| 11/21/2024 | Zealand Pharma A/S | — | Food and Beverage | In-kind items and services | $27.68 | General |
| 11/14/2024 | Eli Lilly and Company | — | — | In-kind items and services | $60.00 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PHASE 1 STUDY TO INVESTIGATE THE EFFECT OF LY3437943 VERSUS PLACEBO ON CALORIE INTAKE AND ENERGY EXPENDITURE IN PARTICIPANTS WITH OBESITY UNDER CALORIE RESTRICTION | ||||||
| 10/24/2024 | Zealand Pharma A/S | — | Consulting Fee | Cash or cash equivalent | $73,875.00 | General |
| 10/24/2024 | Zealand Pharma A/S | — | Travel and Lodging | In-kind items and services | $2,109.95 | General |
| 10/24/2024 | Zealand Pharma A/S | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $768.53 | General |
| 10/01/2024 | Zealand Pharma A/S | — | Consulting Fee | Cash or cash equivalent | $25,000.00 | General |
| 10/01/2024 | Zealand Pharma A/S | — | Consulting Fee | Cash or cash equivalent | $25,000.00 | General |
| 10/01/2024 | Zealand Pharma A/S | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,401.77 | General |
| 10/01/2024 | Zealand Pharma A/S | — | Travel and Lodging | In-kind items and services | $1,631.91 | General |
| 10/01/2024 | Zealand Pharma A/S | — | Travel and Lodging | In-kind items and services | $1,151.90 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| INTERNAL MEDICINE CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $1,400 | 1 |
| A RANDOMIZED, DOUBLE-BLIND, PHASE 1 STUDY TO INVESTIGATE THE EFFECT OF LY3437943 VERSUS PLACEBO ON CALORIE INTAKE AND ENERGY EXPENDITURE IN PARTICIPANTS WITH OBESITY UNDER CALORIE RESTRICTION | Eli Lilly and Company | $60.00 | 1 |
About Dr. Steven Smith, M.D
Dr. Steven Smith, M.D is a Endocrinology, Diabetes & Metabolism healthcare provider based in Orlando, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/01/2009. The National Provider Identifier (NPI) number assigned to this provider is 1497988927.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Steven Smith, M.D has received a total of $435,517 in payments from pharmaceutical and medical device companies, with $322,026 received in 2024. These payments were reported across 173 transactions from 19 companies. The most common payment nature is "Consulting Fee" ($355,599).
Ad
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism
- Location Orlando, FL
- Active Since 09/01/2009
- Last Updated 09/25/2012
- Taxonomy Code 207RE0101X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1497988927
Products in Payments
- NO PRODUCT DISCUSSED (Drug) $22,436
- Saxenda (Drug) $20,201
- Belviq (Drug) $7,272
- Non-Covered Product (Drug) $4,149
- Contrave (Drug) $975.00
- SIGNIA (Device) $175.37
- ETHICON ENDO-SURGERY Curved Adjustable Gastric Band (Device) $108.94
- VSP SYSTEM, VSP CRANIAL (Device) $105.81
- Artis pheno (Device) $61.38
- Korlym (Drug) $49.96
- ORBACTIV (Drug) $20.22
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Endocrinology, Diabetes & Metabolism Doctors in Orlando
Damon Tanton, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $1.4M
Endocrinology, Diabetes & Metabolism $1.4M
Dr. Hanford Yau, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $563,569
Endocrinology, Diabetes & Metabolism $563,569
Dr. Tina Thethi, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $188,396
Endocrinology, Diabetes & Metabolism $188,396
Dr. Deepa Taneja, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $27,443
Endocrinology, Diabetes & Metabolism $27,443
Dr. Maha Zikra, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $26,852
Endocrinology, Diabetes & Metabolism $26,852
Dr. Wendy Huhn, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $17,266
Endocrinology, Diabetes & Metabolism $17,266